Document is current
Any future updates will be listed below
-
Authors
Braun, Alice https://orcid.org/0000-0003-1145-0261
Shekhar, Sudhanshu https://orcid.org/0000-0002-1827-5059
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Straub, Peter
Kraft, Julia https://orcid.org/0000-0001-7306-1179
Panagiotaropoulou, Georgia M.
Heilbron, Karl
Awasthi, Swapnil
Meleka Hanna, Rafael
Hoffmann, Sarah
Stein, Maike https://orcid.org/0009-0002-1514-8385
Lehnerer, Sophie
Mergenthaler, Philipp https://orcid.org/0000-0002-9753-6711
Elnahas, Abdelrahman G.
Topaloudi, Apostolia
Koromina, Maria https://orcid.org/0000-0001-8843-082X
Palviainen, Teemu https://orcid.org/0000-0002-7847-8384
Asbjornsdottir, Bergrun https://orcid.org/0000-0003-4693-1209
Stefansson, Hreinn
Skuladóttir, Astros Th. https://orcid.org/0000-0002-5048-0933
Jónsdóttir, Ingileif https://orcid.org/0000-0001-8339-150X
Stefansson, Kari https://orcid.org/0000-0003-1676-864X
Reis, Kadri
Esko, Tõnu
Palotie, Aarno https://orcid.org/0000-0002-2527-5874
Leypoldt, Frank https://orcid.org/0000-0002-8972-515X
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Fontanillas, Pierre https://orcid.org/0000-0002-8944-4454
,
,
Kaprio, Jaakko https://orcid.org/0000-0002-3716-2455
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Davis, Lea K. https://orcid.org/0000-0001-5143-2282
Paschou, Peristera
Tannemaat, Martijn R. https://orcid.org/0000-0003-2929-0390
Verschuuren, Jan J.G.M. https://orcid.org/0000-0002-4572-1501
Kuhlenbäumer, Gregor
Gregersen, Peter K. https://orcid.org/0000-0003-1613-1518
Huijbers, Maartje G. https://orcid.org/0000-0002-6082-5042
Stascheit, Frauke https://orcid.org/0000-0001-5306-7880
Meisel, Andreas https://orcid.org/0000-0001-7233-5342
Ripke, Stephan https://orcid.org/0000-0003-3622-835X
- License Information
-
More Information
Article History
Received: 21 September 2023
Accepted: 14 October 2024
First Online: 13 November 2024
Competing interests
: The authors declare the following competing interests: A.M. has received speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion Pharmaceuticals, argenx, Axunio, Destin, Grifols, Hormosan Pharma, Janssen, Merck, Octapharma, UCB, and Xcenda. He serves as medical advisory board chairman of the German Myasthenia Gravis Society. A.Th.S., B.Á, H.S., I.J., and K.S. are employees of deCODE/Amgen Inc. F.S. has received speaker’s honoraria from argx and Alexion, as well as honoraria for attending advisory boards for Alexion and UCB Pharma. F.L. is supported by the German Ministry of Education and Research (01GM1908A und 01GM2208), E-Rare Joint Transnational research support (ERA-Net, LE3064/2-1), Stiftung Pathobiochemie of the German Society for Laboratory Medicine and HORIZON MSCA 2022 Doctoral Network 101119457 — IgG4-TREAT and discloses speaker honoraria from Grifols, Teva, Biogen, Bayer, Roche, Novartis, Fresenius, travel funding from Merck, Grifols and Bayer and serving on advisory boards for Roche, Biogen and Alexion. K.H. was formerly employed by and holds stock or stock options in 23andMe, Inc. Murray.S. has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Delix Therapeutics, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. M.G.H. and J.J.G.M.V. are co-inventors on MuSK-related patents. LUMC, M.G.H., and J.J.G.M.V. receive royalties from these patents. LUMC receives royalties from a MuSK ELISA. M.G.H. is a consultant for argenx. Maike.S. has received speaker’s honoraria and honoraria for attendance at advisory boards from argenx and Alexion. P.F. is employed by and holds stock or stock options in 23andMe, Inc. P.M. has been on the board of HealthNextGen. S.L. has received speaker’s honoraria from Alexion, argenx, Hormosan and UCB and honoraria for attendance at advisory boards from Alexion, argenx, Biogen, HUMA, UCB and Roche. S.H. has received speaker’s honoraria from Alexion, argenx, UCB and Roche and honoraria for attendance at advisory boards from Alexion, argenx and Roche. S.H. is a member of the medical advisory board of the German Myasthenia Society, DMG. M.R.T. reports trial support from argenx and Alexion, consultancies for argenx, HUMA and UCB Pharma and research funding from NMD Pharma, with all reimbursements received by Leiden University Medical Center. He is a member of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). The remaining authors declare no competing interests.
